A CircRNA-miRNA-mRNA Network for Exploring Doxorubicin- and Myocet-Induced Cardiotoxicity in a Translational Porcine Model.

Myocet circRNA doxorubicin miRNA network analysis porcine model target prediction

Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
27 Nov 2023
Historique:
received: 06 10 2023
revised: 14 11 2023
accepted: 23 11 2023
medline: 23 12 2023
pubmed: 23 12 2023
entrez: 23 12 2023
Statut: epublish

Résumé

Despite the widespread use of doxorubicin (DOX) as a chemotherapeutic agent, its severe cumulative cardiotoxicity represents a significant limitation. While the liposomal encapsulation of doxorubicin (Myocet, MYO) reduces cardiotoxicity, it is crucial to understand the molecular background of doxorubicin-induced cardiotoxicity. Here, we examined circular RNA expression in a translational model of pigs treated with either DOX or MYO and its potential impact on the global gene expression pattern in the myocardium. This study furthers our knowledge about the regulatory network of circRNA/miRNA/mRNA and its interaction with chemotherapeutics. Domestic pigs were treated with three cycles of anthracycline drugs (DOX,

Identifiants

pubmed: 38136582
pii: biom13121711
doi: 10.3390/biom13121711
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : TEVA Ratiopharm
ID : Teva Ratiopharm Industries

Auteurs

Julia Mester-Tonczar (J)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.

Patrick Einzinger (P)

Research Unit of Information and Software, Institute of Information Systems Engineering, 1040 Vienna, Austria.

Ena Hasimbegovic (E)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.

Nina Kastner (N)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.

Victor Schweiger (V)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.

Andreas Spannbauer (A)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.

Emilie Han (E)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.

Katrin Müller-Zlabinger (K)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.

Denise Traxler-Weidenauer (D)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.

Jutta Bergler-Klein (J)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.

Mariann Gyöngyösi (M)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.

Dominika Lukovic (D)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.

Classifications MeSH